FindTrial
Sign In

CHECKING INTERLEUKIN 6 (IL 6) LEVELS OVER TIME TO PREDICT THE OUTCOMES IN PNEUMONIA PATIENTS WITH WEAK IMMUNE SYSTEMS.

THE ROLE OF SERUM INTERLEUKIN 6 AS A PROGNOSTIC MARKER IN PNEUMONIA IN AN IMMUNOCOMPROMISED HOST

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/07/113222
Enrollment
180
Registered
2026-07-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J181- Lobar pneumonia, unspecified organism

Interventions

Intervention1: Interleukin 6: will be done with 24 hours and again in 72 to 96 hours Intervention2: Nil: Nil

Sponsors

Department of Pulmonary Medicine Christian Medical College Vellore
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients over the age of 18 years admitted in Christian medical college, Ranipet. Clinically diagnosed as pneumonia with radiological evidence of new onset infiltrates in imaging. Patients with known immunocompromised state who are admitted with pneumonia.This includes: Hematopoietic cell transplant within 1 year or requiring treatment for graft- vs-host disease Hematologic malignant neoplasm requiring treatment B-cell aplasia with absolute CD19 B-cell count less than 20 cells/mm within 6 months. Solid organ transplant Solid tumor on treatment HIV co infection Primary immunodeficiency with low immunoglobulins or B/T cell defects Autoimmune disease requiring corticosteroids Liver cirrhosis Chronic kidney disease

Exclusion criteria

Exclusion criteria: Known radiological mimics of pneumonia Ventilator associated pneumonia Patient who are not willing to participate. Patients who are on IL6 inhibitors.

Design outcomes

Primary

MeasureTime frame
TO EVALUATE THE POSITIVE AND NEGATIVE PREDICTIVE VALUE OF SERUM INTERLEUKIN 6 IN PREDICTING 30 DAY MORTALITY IN PNEUMONIA IN AN IMMUNOCOMPROMISED HOST.Timepoint: 30 days—

Secondary

MeasureTime frame
1. TO COMPARE IL6 WITH PROCALCITONIN AND CRP IN PREDICTING TREATMENT RESPONSE IN IMMUNOCOMPROMISED PATIENTS WITH PNEUMONIATimepoint: 30 days;2. TO ASSESS THE ROLE OF IL6 AS A PROGNOSTIC MARKER OF TREATMENT OUTCOME IN PNEUMONIA OF DIFFERENT ETIOLOGIESTimepoint: 30 days;3. TO ASSESS THE ROLE OF IL6 AS A PROGNOSTIC MARKER OF TREATMENT OUTCOME IN PNEUMONIA IN DIFFERENT CATEGORIES OF IMMUNOCOMPROMISED PATIENTSTimepoint: 30 days—

Countries

India

Contacts

Public ContactEsther Varghese

Christian Medical College Vellore

barekar.pratiksha@cmcvellore.ac.in8888790638

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026